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Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate and its use in reducing osteoporosis and cancer-induced osteolysis is
increasing. Recent findings indicated that ZOL has a direct effect on cancer cells. In this study, the effect of ZOL was examined on the
aggressive MDA-MB-231 breast cancer cell line. ZOL induces an important inhibition of cell invasion at low concentrations (1mM).
This is not explained by modifications of proteases involved in cell invasiveness (matrix metalloproteinases and urokinase-type
plasminogen activator), but by a disorganisation of actin cytoskeleton due to RhoA inhibition related to its defective prenylation as it
was reversed by geranylgeraniol (GGOH) and mimicked by the Rho selective inhibitor C3 exoenzyme. In addition, ZOL inhibits the
chemotactic effect induced by stromal cell-derived factor 1(SDF-1), a chemokine greatly involved in cancer metastasis to bone. This
effect is related to both reduction of cell motility induced by RhoA inhibition and to a decreased expression of CXCR-4, the SDF-1
receptor. Finally, ZOL reduces Cox-2 expression and, consequently, the secretion of prostaglandins E2 (PGE2) in a RhoA-
independent manner. This inhibition could contribute to bone protection in breast cancers because PGE2 stimulates osteoclast-
mediated bone resorption. In summary, new insights in the mechanism of ZOL action on aggressive breast cancer cells are
demonstrated and could explain its beneficial action in both the reduction of osteolysis and prevention of metastasis.
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The main cause of treatment failure for cancer patients is
metastasis, a multistep and complex process leading to the
formation of secondary tumours from the original cancer. Breast
cancers preferentially metastasise into the skeleton, causing
specific clinical complications: hypercalcaemia, bone fractures
and pain (Paget, 1889; Mundy, 1997). Bone metastases in breast
cancer account significantly for considerable morbidity and
mortality. Indeed, 80% of patients with metastatic breast cancer
will develop bone metastases and survive for approximately 2 years
(Coleman and Rubens, 1987).
Bisphosphonates (BPs) have proven useful in the treatment of
bone metastases in breast cancer patients and have improved their
quality of life in a number of clinical trials (Theriault et al, 1999;
Lipton et al, 2000). In the first years of BP use, the efficacy of these
substances was thought to lie entirely in the antiproliferative and
apoptotic effects on osteoclasts (Hughes et al, 1995; Selander et al,
1996). However, it is now suggested that these favourable effects
may involve not only the inhibition of osteoclast-mediated bone
resorption but also a direct antitumour effect on cancer cells
(reviewed by Senaratne and Colston, 2002). Additionally, BPs have
been reported to prevent attachment and spreading of breast and
prostate cancer cells onto bone matrices (Boissier et al, 1997). A
recent study using an in vitro model of cell invasion has also
suggested that BPs may inhibit the early event in the formation of
bone metastases (Boissier et al, 2000). Furthermore, several
investigations have reported the inhibition of cell growth and cell
survival by BPs on breast cancer cells (Fromigue et al, 2000;
Senaratne et al, 2000; Hiraga et al, 2001; Jagdev et al, 2001).
While all these data support a direct action on tumour cells
in vitro and is animal models, the molecular mechanism(s) of BP
action remain(s) unclear. Two classes of BPs have been described.
The first generation consists in non-nitrogen-containing BPs that
are metabolised in nonhydrolysable ATP analogues, whereas the
more recent generations, including zoledronic acid (ZOL), are
nitrogen-containing BPs (N-BPs). One possible mechanism by
which N-BPs mediate their effects is based on their ability to
inhibit some of the enzymes involved in the mevalonate (MVA)
pathway, such as farnesylpyrophosphate synthase (van Beek et al,
1999; Bergstrom et al, 2000) and/or geranylgeranylpyrophosphate
synthase (Coxon et al, 2000), thus blocking the generation of
isoprenoid compounds, farnesyl pyrophosphate (FPP) and/
or geranylgeranyl pyrophosphate (GGPP), respectively. These
intermediates are required for post-translational prenylation
(farnesylation and geranylgeranylation) of key regulatory proteins,
a step that is needed to their attachment to the plasma membrane,
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swhere they are fully active and can exert their biological function
(Sinensky, 2000). Consequently, the identification of the proteins
that became unprenylated following N-BP treatment should be of
great interest in understanding the anticancer action of N-BPs.
Among all the potential candidate’s proteins, the small GTPases
of Ras and Rho families could be attractive targets for two reasons.
First, their prenylation is a functional requirement: farnesylation
of Ras and geranylgeranylation of Rho proteins occur, respectively,
through the transfer of a 15-carbon farnesyl isoprenoid from FPP
by the action of farnesyltransferase enzyme (FTase) and one or two
20-carbon geranylgeranyl isoprenoids from GGPP by the action of
geranylgeranyltransferase enzyme (GGTase). Second, the small
GTPases of Ras and Rho families are widely involved in human
tumorigenesis and metastasis, either through constitutive activa-
tion caused by mutations or by overexpression (Adjei, 2001; Sahai
and Marshall, 2002). Then, rendering insensitive to regulatory
signals, they lead to uncontrolled cell proliferation, inhibition of
apoptosis and enhanced angiogenesis, all main aspects of tumour
development. Furthermore, Ras and Rho proteins are also involved
in carcinoma cell motility (reviewed by Oxford and Theodorescu,
2003). For example, activated Ras was shown to stimulate
migration of breast cancer cells (Keely et al, 1999). Additionally,
the regulation of the actin cytoskeleton by Rho GTPases has been
implicated in promoting a variety of cellular processes such as
changes in morphology, motility and adhesion that contribute to
invasion and metastasis of cancer cells in different models, either
in vitro or in vivo (Jaffe and Hall, 2002). In colon carcinoma cells,
expression of a dominant-negative RhoA resulted in the attenua-
tion of cell invasion stimulated by the integrin a6b4 (O’Connor
et al, 2000). In the same way, cells transformed by the activated
RhoA gene (del Peso et al, 1997) or cells expressing a constitutively
active form of RhoA (Yoshioka et al, 1998) have greatly promoted
invasive ability, contributing to the acquisition of a metastatic
phenotype in vivo. Finally, we recently demonstrated that RhoA
activation contributes to breast cancer cell aggressivity (Denoyelle
et al, 2003). Therefore, it would be interesting to determine
whether the anticancer action of N-BPs could be related to the
inhibition of Ras and/or RhoA prenylation, following the decrease
of FPP and/or GGPP synthesis. Recently, a part of the enigma was
resolved by a study demonstrating that ZOL-mediated apoptosis in
breast cancer cells may be initiated by inhibition of Ras
prenylation (Senaratne et al, 2002). However, apoptosis of these
cancer cells occurs only at high concentrations (100mM), higher
than pharmacological concentrations. Although one study sug-
gested that the concentration of BP could reach as high a value as
800mM at the osteoclast–bone interface (Sato et al, 1991), others
reported that an estimated concentration of BP is about 1mM in the
metastatic tumour nest in bone (Usui et al, 1997). Thus, it is
uncertain whether this proposed mechanism of action is also
relevant for the clinical effect of N-BPs. In contrast, only very low
concentrations of ZOL (10
 12–10
 6 M) are able to inhibit cancer
cell invasion (Boissier et al, 2000). Recently, it was proposed that
this inhibitory effect was mediated by the inhibition of the
mevalonate pathway in a prostate cancer cell line, as it was
reversed by geranylgeraniol (GGOH) and farnesol (FOH) (Virtanen
et al, 2002). In the present study, we thus attempted to analyse
whether the impairment of Ras and/or RhoA prenylation could be
a potential mechanism by which ZOL mediated its anti-invasive
effect on the aggressive MDA-MB-231 breast cancer cell line. In
addition, matrix metalloproteinases (MMPs) and urokinase-type
plasminogen activator (u-PA)/u-PA receptor (u-PAR) contribute
to cancer cell invasion (Blasi, 1999). It was already demonstrated
that the inhibition of MDA-MB-231 cell invasion is not explained
by a decrease in MMP secretion as it was observed for
concentrations higher than required for cell invasion inhibition
(Boissier et al, 2000). Then, the effect of ZOL was examined on u-
PA/u-PAR expression in MDA-MB-231 cells.
Next, based on the observation that BPs reduce the release of
bone-derived growth factors and cytokines associated with bone
resorption, which have the potential to attract cancer cells to bone,
it is possible that BP therapy may prevent the development of bone
metastases. Two clinical trials of patients with breast cancer
demonstrated that BPs, given in adjuvant setting, reduce the
incidence of skeletal metastasis with a consequent improvement in
survival (Diel et al, 1998; Powles et al, 2002). However, other
authors reported opposite results (Saarto et al, 2001). Recently, it
was demonstrated that cancer cells use the stromal cell-derived
factor 1 (SDF-1)/chemokine receptor of SDF-1 (CXCR-4) pathway
to spread to bone (Taichman et al, 2002). CXCR-4 is greatly
expressed on malignant breast cancer cells in comparison to
normal epithelial cells (Mu ¨ller et al, 2001). In addition, a high level
of SDF-1 was noted in bone as well as in all target organs for
breast-cancer metastasis and, in Nude mice, a neutralising anti-
CXCR-4 antibody induces a significant inhibition of breast-cancer
metastasis in vivo, indicating a major role of the SDF-1/CXCR-4
pathway in the metastatic process. Therefore, we evaluated the
effect of ZOL on CXCR-4 expression and on the chemotactic effect
induced by SDF-1.
Finally, it is well established that a ‘vicious cycle’ between cancer
cells and osteoclasts favours cancer-induced osteolysis (Okada
et al, 2000). It was demonstrated that invasive mammary cell lines,
which constitutively express inducible Cox-2, enhance osteoclast
formation through the production of high levels of prostaglandins
E2 (PGE2) and subsequently induce an increase of osteolysis (Ono
et al, 2002). We thus examined whether ZOL could affect the
constitutive expression of Cox-2 in MDA-MB-231 cells.
MATERIALS AND METHODS
Cell culture
A human breast carcinoma cell line MDA-MB-231 was used in this
study. MDA-MB-231 cells were grown in RPMI 1640 medium
(Eurobio, Les Ulis, France), 10% foetal calf serum (FCS, Costar,
Brumath, France), 2mML -glutamine (Gibco BRL, New York, NY,
USA), 100IUml
 1 penicillin (Sarbach, Suresnes, France) and
100mgml
 1 streptomycin (Diamant, Puteaux, France). Cells were
cultured at 371C in a humidified 5% CO2 atmosphere. Then,
adherent cells were incubated with indicated concentrations of
ZOL (Zometa
s, Novartis) during different periods. The role of
MVA pathway enzymes was studied by treating cells with 100mM
MVA, 10mM FOH (analogue of FPP), 10mM GGOH (analogue of
GGPP), or 10mM squalene (SQUA) (Sigma, Saint Quentin Fallavier,
France). The farnesyltransferase inhibitor FTI-277, the geranylger-
anyltransferase inhibitor GGTI-298 and the C3 exoenzyme from
Clostridium botulinum C3 transferase (C3 Exo), a specific inhibitor
of RhoA, were purchased from Calbiochem (San Diego, CA, USA).
Cell proliferation
For the proliferation assay, we used the minimal concentration of
FCS (2%) to allow sufficient viability of MDA-MB-231 cells. Briefly
after trypsinisation, the cells were seeded at a concentration of
5 10
4cells per well in a 24-well plate (Costar, Cambridge, MA,
USA) and incubated with ZOL. Cell number was measured on day
3 for MDA-MB-231 with a particle counter (Coulter Z1,
Coultronics, France) after detachment with a nonenzymatic cell
dissociation solution (Sigma).
Flow cytometry analysis
Flow cytometry analysis was performed as previously described
(Denoyelle et al, 2001). Tumour cells were detached by a
nonenzymatic cell dissociation solution and washed twice in cold
PBS. The phosphatidylserine expression on the surface of breast-
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scancer cells was determined using an Annexin V commercial kit
(Immunotech, Marseille, France). Briefly, cells were incubated with
10ml of a fluorescein–isothiocyanate (FITC)-conjugated Annexin
V. Staining with propidium iodide (0.3mgml
 1) was performed to
confirm the absence of cell membrane permeability. u-PAR
expression on MDA-MB-231 cells was determined by direct
immunofluorescence, while u-PA and CXCR-4 were detected by
indirect immunofluorescence. Approximately 5 10
5 cells were
incubated for 15min at 41C with 5ml of specific antibodies
(1mgml
 1). After two washes, the cell suspension was immedi-
ately analysed in a flow cytometer (EPICS XL-MCL, Coulter, USA),
when antibody was directly conjugated to phycoerythrin (u-PAR,
Immunotech), while another 15min incubation with an FITC-
labelled F(ab0)2 fraction of goat anti-mouse IgG1 (10mgml
 1,
Immunotech) was carried out for the detection of u-PA (American
Diagnostic, Greenwich, CT, USA) and CXCR-4 (R&D Systems,
Abingdon, UK) antibodies. Data are expressed as the percentage of
fluorescent cells or as the specific mean channel fluorescence
intensity (MFI). Specific MFI was calculated for each sample by
subtracting the background MFI produced by an irrelevant
antibody from the MFI generated by the specific antibody.
Invasion assay on a Matrigel-coated membrane
in a Transwell
An 8-mm-diameter Pore Transwell (Dutscher, Brumath, France)
were coated with 500ml of Matrigel (Becton Dickinson Europe,
Meylan, France) diluted at 100mgml
 1. Breast tumour cells were
detached by the nonenzymatic cell dissociation solution, washed
twice with PBS, and 2 10
5 cells in RPMI 1640 with 0.2mgml
 1
bovine serum albumin (BSA, Sigma) were seeded in the upper
chamber of the Matrigel-coated insert. The lower chamber was
filled with 1ml of RPMI 1640 together with 2mgml
 1 BSA and
basic fibroblast growth factor (bFGF, 20ngml
 1) (R&D Systems)
to induce invasion. The chemotactic effect induced by SDF-1 was
studied by realising a gradient, which was achieved by adding SDF-
1 (200ngml
 1) in the lower compartment. After 18h of incuba-
tion, the nonmigrating cells in the upper chamber were gently
scraped, and the adherent cells present on the lower surface of the
insert were stained by May–Gru ¨newald–Giemsa and counted by
light microscopy, 10 fields (magnification  200) were counted for
each insert. To verify that observed responses are dependent on
CXCR-4 receptor binding, the cells were incubated for 30min at
41C with 100mg of the CXCR-4 antibody before being seeded in the
upper chamber.
Separation of particulate and cytosolic fractions
After different incubation times with ZOL, separation of particu-
late and cytosolic fractions was performed as previously described
(Denoyelle et al, 2003). Briefly, MDA-MB-231 cells were washed
with cold PBS, lysed in ice-cold buffer that contained phosphatase
and protease inhibitors and centrifuged at 100000g for 30min at
41C. The supernatant was collected as the cytosolic fraction. Pellets
were homogenised in the above-mentioned lysis buffer containing
2% Triton X-114 (Sigma) and centrifuged at 800g for 10min at
41C. The supernatant was collected and was referred to as the
membrane fraction. The protein concentration was determined
according to the method of Bradford using the Bio-Rad protein
assay (Hercules, CA, USA).
Confocal microscopy analysis of actin cytoskeleton on
MDA-MB-231 cells
MDA-MB-231 was cultured in four-well Glass Lab-Tek chamber
slides (Nunc, Roskilde, Denmark). The confocal microscopy
analysis of actin filaments was performed after an 18h incubation
with 1mM ZOL as previously described (Denoyelle et al, 2001).
Actin filaments were visualised by phalloidin–tetramethylrhoda-
mine–isothiocyanate (TRITC) conjugate (Sigma). Computer-
assisted image analysis of fluorescence was performed using a
confocal microscopy scanning laser microscope (Leica TCS,
wavelength excitation 488nm, emission 580nm).
Western blotting
Equal amounts of protein extracts (50mg) were subjected to PAGE
(15% for RhoA, Ras and 10% for Cox-2) under denaturing
conditions (SDS–PAGE). Proteins were electrotransferred onto
polyvinylidene difluoride (PVDF) membrane (Amersham Pharma-
cia Biotech, Saclay, France), as described (Denoyelle et al, 2001).
Membranes were immunoblotted overnight with RhoA or pan-Ras
polyclonal antibody (1:500, from Santa Cruz, SA, USA) or Cox-2
monoclonal antibody (1:250, from Transduction laboratories),
followed by incubation with the appropriate horseradish perox-
idase-conjugated secondary antibody (1:10000, Dako, Trappes,
France), then developed with enhanced chemoluminescence
reagent (ECL) solution (Amersham Pharmacia Biotech) and
exposed to Kodak X-OMAT films. For reprobing, membranes
were stripped with a solution containing 50mM Tris-HCl (pH 6.8),
2% SDS and 100mM 2-mercaptoethanol for 30min at 501C. Blots
were rehybridised with b-actin polyclonal antibody (1:5000,
Sigma) to control protein loading. Each immunoblot is represen-
tative of three distinct experiments.
Total RNA extraction and RT–PCR
After the indicated incubation time of MDA-MB-231 cells with
1mM ZOL, cells were detached and washed twice in PBS. Total RNA
extraction was performed using the SV Total RNA Isolation system
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Primers were chosen using biomolecular sequence
databases (Genbank) and oligonucleotides were synthesised by
ProOligos (Paris, France); the sequences were as follows: cox-2
(forward primer, 50-cggacaggattctatggaga-30; reverse primer, 50-
caatcatcaggcacaggagg-30), GAPDH (forward primer, 50-cggagt-
caacggatttggtcgtat-30; reverse primer, 50-cgctcctggaagatggtgatgg-
30). RT–PCR was carried out using the ‘Access RT–PCR system’
(Promega) according to the manufacturer’s instructions. After
PCR, 15ml of products and standard DNA ladder were run on a
1.5% agarose gel stained with ethidium bromide. The predicted
sizes for cox-2 and GAPDH PCR products were, respectively, 300
and 222bp.
ELISA assay
The measurement of PGE2 was performed using an ELISA assay,
according to the manufacturer’s instructions (R&D Systems).
Statistical analysis
Statistical significance was determined by the Student’s t-test using
the InStat Software (Sigma).
RESULTS
Apoptosis and inhibition of MDA-MB-231 cell
proliferation requires high concentrations of ZOL
The effects of various concentrations of ZOL on the growth rates of
MDA-MB-231 cells were studied by measuring the cell number in
the absence or presence of ZOL at different concentrations after a
3-day incubation. Furthermore, the effects of ZOL on apoptosis
were also assessed by flow cytometry using Annexin V conjugated
to fluorescein, an early indicator of apoptosis. Positive control was
done using Taxol (a well-known mitotic spindle toxin). ZOL had
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sno effects on MDA-MB-231 cell proliferation at low concentrations
(o10mM) (Figure 1). In contrast, cell numbers were significantly
reduced at a concentration of 100mM ZOL. Likewise, ZOL did not
induce apoptosis on this cell line for low concentrations, whereas
Annexin V binding was detected at the tumour cell surface when
they were treated with 100mM ZOL (Table 1).
Inhibition of MDA-MB-231 cell invasion through Matrigel
by low concentrations of ZOL
Under our conditions, as shown in Figure 2, MDA-MB-231 cells
were highly invasive in Matrigel-coated chambers. Treatment of
MDA-MB-231 cells for 18h with ZOL at low concentrations (from
10
 7 M) inhibited MDA-MB-231 cell invasion in the in vitro
invasion assay in a dose-dependent manner (Figure 2). The
number of invading cells was decreased by 62.173.8% (Po0.01)
following treatment with 1mM ZOL. Consequently, a 1mM
concentration of ZOL was chosen for treatment of MDA-MB-231
cells for the following experiments.
Inhibition of MDA-MB-231 cell invasion by ZOL is
reversed by GGOH
It was reported that N-BPs inhibit enzymes of the MVA pathway,
and thus the synthesis of isoprenoid intermediates. To determine
whether the inhibition of isoprenoids by ZOL is responsible for its
inhibitory effect on cell invasion, we tested whether the inhibition
of cell invasion by ZOL was reversed by the MVA pathway
metabolites (MVA, FOH, GGOH and SQUA). It was verified that
the simple addition of these intermediates has no effects on the
invasion of untreated MDA-MB-231 cells (data not shown). The
invasion-suppressive effect of ZOL on MDA-MB-231 cells was
circumvented by the addition of 10mM GGOH, which restores
geranylgeranylation (the percentages of invading cells in compar-
ison to untreated cells were, respectively, for 1mM ZOL-treated
cells, 37.973.8 and 92.472.8% in the absence and presence of
GGOH) (Figure 3). In contrast, MVA, SQUA and FOH (which
restores farnesylation) did not reverse the anti-invasive effect of
ZOL. In addition, to confirm that the anti-invasive effect of ZOL is
mediated by inhibiting protein geranylgeranylation, we next
examined whether the GGTase I inhibitor, GGTI-298, mimicked
the effect of ZOL. As shown in Figure 3, treatment of MDA-MB-231
cells with GGTI-298 caused a significant decrease of cell invasion,
while FTI-277, an inhibitor of FTase, at the same concentrations,
was devoid of effect. Therefore, these results suggest that
inhibition of geranylgeranylated proteins (such as Rho) rather
than farnesylated proteins (such as Ras) seems to be important to
explain the anti-invasive action of ZOL. Since the small GTPase
RhoA requires geranylgeranylation to promote cancer invasion, we
suggested that RhoA could represent a potential candidate to
mediate ZOL effects. In support of this hypothesis, it was found
that the addition of Clostridium botulinum C3 transferase (C3
exoenzyme), a widely accepted RhoA inhibitor (Sekine et al, 1989),
mimicked ZOL action on MDA-MB-231 cells.
T
o
t
a
l
 
c
e
l
l
s
 
 
0 
50 000 
100 000 
150 000 
200 000 
250 000 
300 000 
350 000 
Control
Zoledronic acid (ZOL) 
* * 
100 M  10 M 1 M   100 nM 10 nM 
Figure 1 Effect of zoledronic acid (ZOL) on MDA-MB-231 cell
proliferation. Cells (5 10
5) were seeded per well and cells were counted
in a particle counter after 3 days of culture with a minimal concentration of
FCS (2%) to ensure viability of the cells in the presence or absence of
indicated concentrations of ZOL. Results are mean7s.e.m. of four
independent experiments (**Po0.01).
Table 1 Zoledronic acid (ZOL) induces apoptosis in MDA-MB-231 cells only at high concentrations
ZOL (lM)
Control 0.01 0.1 1 10 100 Taxol
Annexin V 7.971.7 12.672.3 8.272.8 9.973.2 13.772.6 35.2*75.3 64.2**74.8
Propidium iodide 4.271.8 6.772.3 5.973.1 5.672.9 6.571.2 5.171.9 6.972.5
Confluent MDA-MB-231 cells were incubated for 18h with ZOL at indicated concentrations. Taxol was used as positive
control. Results are the mean7s.e.m. of three independent experiments and are expressed as the percentage of positive
cells (Bold indicates significance; *Po0.05, **Po0.01).
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Figure 2 Effect of increasing concentrations of zoledronic acid (ZOL) on
MDA-MB-231 cell invasiveness through Matrigel. MDA-MB-231 cells were
treated for 18h by indicated concentrations of ZOL. After detachment and
two washes in PBS, 2 10
5 cells were added in the upper Transwell
chamber coated with Matrigel, as described in the Materials and Methods
section. After 18h incubation at 371C, the cells in the upper part of the
invasion chamber were gently detached and cells that had traversed the
filter were counted by light microscopy after May–Gru ¨newald–Giemsa
coloration. In all, 10 fields (magnification  200) were counted for each
insert. Data are expressed as the percentage (as compared to control) of
the mean7s.e.m. of five independent experiments. (*Po0.05, **Po0.01).
Anticancer action of zoledronic acid
C Denoyelle et al
1634
British Journal of Cancer (2003) 88(10), 1631–1640 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sZOL mediates MDA-MB-231 cell invasion inhibition by
preventing RhoA translocation from the cytosol to
cell membrane
Since the small GTPase RhoA must be targeted to the plasma
membrane for its activation (Yoshioka et al, 1998), we examined
the effect of ZOL on the translocation of RhoA protein from the
cytosol to the membrane fraction in MDA-MB-231 cells. In control
MDA-MB-231 cells, RhoA is predominantly associated with the cell
membrane, suggesting that in these cancer cells the overexpression
of RhoA facilitates its translocation from the cytosol to the cell
membrane, as previously described (Yoshioka et al, 1998; Fritz
et al, 1999). In contrast, after treatment with 1mM ZOL for 18h,
RhoA was almost found in the cytosol fraction and the amount of
this protein associated with the cell membrane was greatly reduced
(Figure 4A). In addition, we observed that the inhibiting effect of
ZOL on the RhoA membrane localisation was prevented by the
addition of GGOH, but not FOH. C3 exoenzyme was used as
positive control. Therefore, these results suggested that RhoA
seems to be the main target of the inhibitory effect induced by ZOL
on cell invasion. Additionally, because it was recently suggested
that the treatment of MDA-MB-231 with high concentrations of
ZOL inhibits generation of FPP leading to decreased prenylation of
Ras (Senaratne et al, 2002), we also analysed the effect of ZOL on
the cellular localisation of Ras. In control cells, Ras was
predominantly associated with cell membrane fraction because
MDA-MB-231 cells are characterised by a Ras mutation, leading to
its constitutive activation. According to our results (see above),
ZOL did not inhibit the translocation of Ras from cytoplasm to the
cell membrane at low concentration (1mM) after 18h of treatment
(Figure 4B).
ZOL induces a disorganisation of actin cytoskeleton and a
loss of stress fibres formation in MDA-MB-231 cells
Since RhoA is engaged in cytoskeleton reorganisation to promote
cancer invasion, we studied the effect of ZOL on the morphology of
MDA-MB-231 breast cancer cells. Untreated MDA-MB-231 cells
were flat and well spread. In contrast, ZOL induced dramatic
morphological changes characterised by a cell rounding and a
disorganisation of actin cytoskeleton accompanied by a loss of
stress fibres formation, which were clearly evidenced by confocal
microscopy. Moreover, these morphological changes were rescued
by the addition of GGOH, but not FOH (Figure 5). Importantly, C3
exoenzyme mimicked the morphological changes induced by ZOL
(Figure 5).
ZOL inhibits the expression of u-PAR but not of u-PA
in MDA-MB-231 cells
As u-PA associated with its receptor (u-PAR) is required to
stimulate invasion of cancer cells (Blasi, 1999), we studied the
effect of ZOL on the u-PA and u-PAR expressions by flow
cytometry. After an 18h incubation with 1mM ZOL, we observed a
dose-dependent decrease of u-PAR antigen on the MDA-MB-231
cell surface (60% decrease) (Table 2). In contrast, the inhibition of
u-PA expression was only observed for 100mM ZOL, but not at
lower concentrations (Table 2).
Inhibition by ZOL of the chemotactic effect induced SDF-1
and CXCR-4 expression on MDA-MB-231 cells
Since cancer cells use the SDF-1/CXCR-4 pathway to spread to
bone (Taichman et al, 2002), we investigated whether ZOL may
affect the SDF-1/CXCR-4 chemotaxis mechanism. Firstly, we
verified that the addition of SDF-1 to the lower chamber induced
invasion of MDA-MB-231 cells through a reconstituted basement
membrane (Matrigel). The percentage of cells that invade the
Matrigel was at least four times higher when SDF-1 was added in
the lower chamber, indicating a potent chemotactic effect of SDF-1
on MDA-MB-231 cells (Figure 6). As control, this SDF-1-mediated
invasion could be abrogated by the addition of SDF-1 to both the
upper and lower compartments of Boyden’s chamber, confirming
the specificity of the chemotactic response induced by this
chemokine. Moreover, the addition of CXCR-4 neutralising
antibody to the top of the culture chamber, but not an isotype
control, decreased MDA-MB-231 cell invasion. This provides
verification that the chemotactic effect induced by SDF-1 is mostly
dependent on CXCR-4 receptor binding (Figure 6). Next, the
ability of ZOL to influence SDF-1-induced breast carcinoma
chemotactic effect was studied. The number of cells that invade
Matrigel was roughly the same in untreated cells and cells treated
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Figure 3 Effect of the mevalonate (MVA) pathway metabolites on
zoledronic acid (ZOL)-induced MDA-MB-231 cell invasion inhibition –
Comparison with the effect of FTase inhibitor (FTI-277), GGTase inhibitor
(GGTI-298) and C3 exoenzyme. MDA-MB-231 cells were treated for 18h
with 5mgml
 1 C3 exoenzyme or 10mM FTI-277 or 10mM GGTI-298 or
1mM ZOL in the presence or absence of different MVA pathway
metabolites–100mM mevalonate (MVA), 10mM farnesol (FOH), 10mM
geranylgeraniol (GGOH) and 10mM squalene (SQUA) and experiments
were performed as indicated in Figure 2. Data are expressed as the
percentage (as compared to control) of the mean7s.e.m. of five
independent experiments. Significant difference from nontreatment control
(**); from ZOL-treated cells (
##)( **
,##Po0.01).
Ras 
(21 kDa)
RhoA 
(21 kDa)
MCMC
MC MC
MCMCMC
Control 
Control 
Zoledronic
 Acid (1 M)  
Zoledronic
 acid (1 M)  
ZOL+GGOH ZOL+FOH C3 Exo.
Figure 4 Zoledronic acid (ZOL) prevents the translocation of RhoA
from cytoplasm to the cell membrane in MDA-MB-231 cells (A), but has
no effect on Ras localisation (B). (A) MDA-MB-231 cells were treated with
ZOL (1mM) in the presence or absence of GGOH (10mM) or FOH (10mM)
for 18h. C3 exoenzyme was used as positive control. (B) MDA-MB-231
cells were treated or not for 18h with 1mM ZOL. Cells were then lysed
and the membrane (M) and cytosolic (C) fractions were separated by
ultracentrifugation. RhoA (A) and Ras (B) were detected by immunoblot-
ting using RhoA and Ras polyclonal antibodies. These results are
representative of three independent experiments.
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swith both SDF-1 and ZOL. Therefore, ZOL inhibited both invasion
and SDF-1 chemotactic effect of breast-cancer cells. However, in
contrast to cell invasion, the inhibition of chemotactic effect by
ZOL was only rescued by 60% by GGOH and partially mimicked by
GGTI-298. In addition, the reduction of SDF-1-induced invasion
by C3 exoenzyme is much lower than that observed with ZOL-
treated cells (30 vs 70%) (Figure 6). These results indicate that the
decrease of cell motility induced by RhoA inhibition was not the
only mechanism responsible for this inhibition. Recently, a strong
cell-surface expression of CXCR-4, the SDF-1 receptor, was
described on the aggressive MDA-MB-231 breast-cancer cell line
(Mu ¨ller et al, 2001). We confirmed these data on these cells (59.8%
of positive cells) by flow cytometry (Table 3). Subsequently, the
effect of ZOL was tested on CXCR-4 expression. As indicated in
Table 3, an 18h treatment with 1mM ZOL reduced the CXCR-4
expression from 59.8 to 15.7% of positive cells. This decrease of
CXCR-4 expression by ZOL was not reversed by GGOH and FOH
and was not induced by C3 exoenzyme.
Inhibition of Cox-2 expression and PGE2 release by ZOL
on MDA-MB-231 cells
One mechanism that contributes to osteoclast activation and
metastasis-induced osteolysis is the release of PGE2 by cancer cells
(Ono et al, 2002). Therefore, we evaluated the action of ZOL on
Cox-2 mRNA and protein expression in MDA-MB-231 cells.
According to previous studies (Liu and Rose, 1996), MDA-MB-
231 cells expressed a high constitutive level of inducible Cox-2,
which was observed at both mRNA and protein levels. Interest-
ingly, the Cox-2 transcript was greatly decreased from 6h after
1mM ZOL treatment (Figure 7A). In addition, when MDA-MB-231
cells were treated with 1mM ZOL for 18h, a significant decrease of
Cox-2 protein expression was noted (Figure 7B). As a consequence,
it was found that treatment of cancer cells with ZOL induced a
decrease in Cox-2 enzyme activity: a high level of PGE2
(375.4726.7pgmg
 1 protein in 24h) was observed in the medium
of untreated cells whereas exposure of cells to 1mM ZOL caused a
clear decrease in PGE2 secretion (196.4718.9pgmg
 1 protein in
24h, Po0.01) (Figure 7D). Importantly, the inhibition of Cox-2
expression by 1mM ZOL was not reversed by GGOH and FOH. This
indicates that RhoA inhibition seems not to be involved in Cox-2
inhibition by ZOL. This RhoA-independent effect was also
confirmed by the absence of the effect of C3 exoenzyme on Cox-
2 at transcript and protein levels on these breast cancer cells
(Figures 7B and C). This was also in good agreement with the
observations that GGOH did not reverse the effect of ZOL on PGE2
secretion (225.8738.6pgmg
 1 protein in 24h) and that C3
exoenzyme was also devoid of effect on PGE2 secretion.
DISCUSSION
During the last years, many investigations have shown that BPs are
targeted towards osteoclasts and protected against metastasis-
induced osteolysis. However, BPs can also act directly on cancer
cells. In the first part of this study, we analysed the action of ZOL, a
Control 
  ZOL+GGOH     ZOL+FOH  
ZOL 
C3 Exo. 
AB
CD E
Figure 5 Morphological changes and reorganisation of actin cytoskeleton on MDA-MB-231 cells treated by zoledronic acid (ZOL). – Comparison with
C3 exoenzyme. The actin cytoskeleton of MDA-MB-231 cells was labelled by phalloidin-TRITC and analysed by confocal microscopy. On untreated cells
(A), note the actin stress fibres and cell spreading. Treatment for 18h with 1mM ZOL (B) induced morphological changes of cells associated with
disorganisation of actin stress fibres. The modifications induced by ZOL were reversed by geranylgeraniol (GGOH) (C) but not by farnesol (FOH) (D) and
mimicked by C3 exoenzyme (E) (Scale bar¼10mM).
Table 2 Effect of zoledronic acid (ZOL) on u-PA and u-PAR expression
on MDA-MB-231 cells
ZOL (lM)
0.01 0.1 1 10 100
u-PA 93.674.3 97.275.6 84.874.6 73.777.3 67.3*75.8
u-PAR 96.675.1 64.279.4 43.6**74.6 45.7*77.1 39.3**74.9
MDA-MB-231 cells were incubated for 18h with increasing concentrations of ZOL
and u-PA and its receptor u-PAR expressed at the membrane were analysed by flow
cytometry. Data are expressed as the percentage (as compared to the controls) of
the mean fluorescence intensity (MFI) of four separate experiments. (Bold indicates
significance; *Po0.05, **Po0.01).
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sthird-generation N-BP that is increasingly being used in the
treatment of bone metastases, on the proliferation and invasive-
ness of highly aggressive breast-cancer cells MDA-MB-231.
In agreement with recent studies already published (Fromigue
et al, 2000; Hiraga et al, 2001; Jagdev et al, 2001), it was shown that
ZOL inhibits MDA-MB-231 cell proliferation, but only for high
concentrations (4100mM) which are certainly higher than the
pharmacological concentrations obtained in vivo. However, such
elevations of BP concentrations cannot be excluded, for short
periods, within the bone metastases as the result of locally
increased bone resorption in patients. The decrease of cell
proliferation induced by ZOL could be related to the induction
of apoptosis because it occurs in these cells at the same
concentrations.
Next, the effect of ZOL was also studied on MDA-MB-231 cell
invasion. After an 18h incubation time, ZOL, at low concentrations
(from 100nM), displayed a potent anti-invasive property on MDA-
MB-231 cells (62% decrease at 1mM) in the in vitro invasion assay
through Matrigel. As ZOL did not induce apoptosis at these
concentrations, the possibility that ZOL interfered with invasion
by inducing cell death was excluded. This is also in agreement with
the reported observations of Boissier et al (2000).
Additionally, we attempted to determine the mechanism
involved in the ZOL-induced anti-invasive effect on MDA-MB-
231 cells. This mechanism did not imply proteases involved in
tumour invasion by inducing the degradation of the extracellular
matrix (ECM). Indeed, neither MMP secretion nor u-PA expres-
sion was modified at concentrations that inhibit cell invasion. Only
high concentrations were needed to reduce the secretion of both
MMP-2 and MMP-9 (Boissier et al, 2000) and u-PA expression in
MDA-MB-231 cells as shown in Table 2. In contrast, u-PAR
expressed on the cell surface of MDA-MB-231 cells was
dramatically reduced by ZOL at low concentrations (Table 2).
u-PAR is a ligand for vitronectin, which is a common protein in
mature bone microenvironment (Cooper et al, 2002). Conse-
quently, the decrease of u-PAR by ZOL could contribute to the
previously reported prevention of breast-cancer cell attachment
onto bone matrices (van der Pluijm et al, 1996; Boissier et al,
1997).
Since the small GTPases of Ras and Rho families have to be
prenylated to play an essential role in carcinoma cell invasion
(Oxford and Theodorescu, 2003), we attempted to assess if the
anti-invasive action of ZOL could be related to Ras and/or RhoA
inactivation, following the decreased formation of FPP and GGPP,
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Figure 6 Zoledronic acid (ZOL) inhibits the chemotactic effect induced by SDF-1 on MDA-MB-231 cells – Partial reversion by geranylgeraniol (GGOH).
Confluent MDA-MB-231 cells were treated for 18h with 5mgml
 1 exoenzyme or 10mM FTI-277 or 10mM GGTI-298 or 1mM ZOL in the presence or
absence of GGOH and farnesol (FOH) and seeded into the upper chamber of Transwell coated with Matrigel, and a gradient of SDF-1 (100ngml
 1) was
established by placing the chemokine in the lower chamber. Then the invasion was measured as described in Figure 2. The inhibitory effect of ZOL was
compared with that of C3 exoenzyme and of neutralising antibody against CXCR-4. Results are expressed as the percentage (as compared to control) of
the mean7s.e.m. of five independent experiments. Significant difference from nontreatment control (*); from ZOL-treated cells (
#)( *
,#Po0.05, **Po0.01).
Table 3 Effect of zoledronic acid (ZOL) on the expression of chemokine
receptor CXCR-4 on MDA-MB-231 cells
ZOL (1lM)
Control ZOL (1lM) +GGOH +FOH C3 Exo.
59.873.1 15.7**72.3 18.674.7 13.171.5 47.576.1
MDA-MB-231 cells were treated or not by 1mM ZOL with or without geranylgeraniol
(GGOH) and farnesol (FOH). The effect of ZOL was compared with that of C3
exoenzyme (C3 Exo). The chemokine receptor of SDF-1, CXCR-4, was detected by
flow cytometry by indirect immunofluorescence using an FITC-conjugated anti-
mouse Ab. Results are the mean7s.e.m. of four independent experiments and are
expressed as the percentage of positive cells (Bold indicates significance; **Po0.01).
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srespectively. In this study, it was demonstrated that GGOH, which
restores geranylgeranylation, but not FOH, which restores
farnesylation, reversed the effect of ZOL, suggesting that the
inhibition of protein(s) geranylgeranylation rather than farnesyla-
tion seems to account for ZOL anti-invasive action. To test this
hypothesis further, the effect of FTI-277 and GGTI-298 that
potently and selectively inhibit FTase and GGTase, respectively,
was compared with the action of ZOL on MDA-MB-231 cell
invasiveness. These inhibitors have been widely used to identify
the prenylated proteins involved in the biological functions of
various cell types (Lerner et al, 1995; Vogt et al, 1996). The
incubation of MDA-MB-231 cells with GGTI-298 mimicked the
anti-invasive effect of ZOL, whereas FTI-277 was devoid of effect.
Thus, inhibition of protein geranylgeranylation seems to be
important to explain the anti-invasive action of ZOL. This effect
was also mimicked by C3 exoenzyme, which is a specific inhibitor
of RhoA, but not for other Rho subfamily members, Rac and Cdc42
(Boquet, 1999). Therefore, it was suggested that the inhibition of
cell invasion by ZOL could be related to the inhibition of RhoA cell
signalling. This was also supported by our observation showing
that ZOL at low concentrations prevents the translocation of RhoA
from cytoplasm to the cell membrane. Strikingly, there was a
parallel between ZOL inhibition of cell invasion, the decrease in
membrane-associated RhoA and the morphological changes
characterised by a disorganisation of actin cytoskeleton, as shown
by confocal microscopy. Therefore, RhoA inhibition by ZOL could
be responsible for its anti-invasive effect on MDA-MB-231 cells by
decreasing their motility as a result of the disorganisation of actin
cytoskeleton accompanied by a loss of stress fibres. Additionally,
Ras inactivation did not appear to be involved in the inhibition of
MDA-MB-231 cell invasion because, at the same low concentra-
tion, Ras is not inactivated by ZOL, as clearly evidenced by its
membrane localisation. Finally, the decrease in cell invasion
induced by ZOL was not modified by treatment with 10mM SQUA,
the late metabolite in the cholesterol synthesis pathway, suggesting
that regulation of cellular cholesterol level was not involved in this
effect.
In contrast to the effect of ZOL on cell invasion, the inhibition of
cell proliferation seems independent of RhoA inactivation because
at the concentration for which RhoA is inhibited, cell proliferation
and apoptosis are unaltered. This inhibition seems more likely due
to the inhibition of Ras prenylation as recently demonstrated by
Senaratne et al (2002).
In the second part of this study, it was shown that ZOL inhibits
the chemotactic effect induced by the chemokine SDF-1 on MDA-
MB-231 cells. This observation constitutes an important addition
to the mechanistic understanding of how BPs, given in adjuvant
setting, could prevent the development of bone metastases as
shown by two clinical trials (Diel et al, 1998; Powles et al, 2002).
Moreover, we attempted to elucidate whether this effect of ZOL
could be explained by the inhibition of the MVA pathway, and
more particularly by RhoA inactivation. However, this inhibition
was incompletely circumvented by GGOH and only partially
mimicked by GGTI-298, suggesting that in contrast to the
inhibitory effect induced by ZOL on cell invasion, which could
be mainly explained by the disorganisation of cytoskeleton
induced by RhoA inhibition, an additional mechanism may occur.
Indeed, we demonstrated that the ZOL induces also a potent
inhibition of CXCR-4 expression on MDA-MB-231 cells, which was
not reversed by GGOH and not mimicked by C3 exoenzyme.
Consequently, at least two mechanisms cooperate to induce this
inhibiting effect induced by ZOL; one related to defective actin
stress fibres formation responsible for the loss of traction forces
required for cell motility, which is RhoA-dependent, and the other
related to decreased CXCR-4 expression, which is RhoA-indepen-
dent. This effect of ZOL could be crucial for the inhibition of
cancer cell metastasis in bone, as it was reported that neutralising
anti-human CXCR-4 monoclonal antibody suppresses metastases
in a breast-cancer model (Mu ¨ller et al, 2001).
Finally, in bone, breast-cancer cells interact mainly with bone-
resorbing osteoclasts, supplying them with stimulatory factors,
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Figure 7 Effect of zoledronic acid (ZOL) on Cox-2 mRNA, protein
levels and activity in MDA-MB-231 cells – Comparison with C3
exoenzyme. (A) Time course of ZOL on Cox-2 mRNA expression.
MDA-MB-231 cells were treated for 3, 6 or 12h with or without 1mM
ZOL. RNA was extracted and analysed by RT–PCR. Sizes of PCR products
for Cox-2 and GAPDH were, respectively, 300 and 222bp. (B) Effect of
ZOL on Cox-2 mRNA expression. MDA-MB-231 cells were incubated for
12h with C3 exoenzyme (5mgml
 1) or with 1mM ZOL with or without
geranylgeraniol (GGOH) (10mM) and farnesol (FOH) (10mM) and
compared with untreated cells. RNA was extracted and analysed by
RT–PCR. Sizes of PCR products for Cox-2 and GAPDH were,
respectively, 300 and 222bp. (C) Effect of ZOL on Cox-2 protein level.
MDA-MB-231 cells were incubated with or without ZOL for 18h and
Cox-2 protein expression was examined by Western blot, using a
monoclonal anti-Cox-2 antibody. Blots were developed with the enhanced
chemoluminescence reagent (ECL). The membrane was also probed with
b-actin to confirm equal loading. (D) Effect of ZOL on the secretion of
PGE2 in the supernatant of MDA-MB-231 cells. The levels of PGE2 were
measured by ELISA assay on supernatants of control and ZOL (1mM)-
treated MDA-MB-231 cells in the presence or absence of GGOH and
FOH. The effect of ZOL was compared with C3 exoenzyme. Results are
mean7s.e.m. of three independent experiments and are expressed in
picograms of PGE2 per microgram of protein (**Po0.01).
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swhich lead to disruption of bone structure and release of stroma-
bound factors that in turn stimulate the growth of cancer cells (Yin
et al, 1999). Invasive breast cancers, which constitutively express
inducible Cox-2, enhance osteoclast formation through the
production of high levels of PGE2 and subsequently an increase
of osteolysis (Ono et al, 2002). As an important mechanism
involved in the effect of BPs in bone marrow metastasis is the
reduction of osteoclast-induced bone osteolysis, we also analysed
whether ZOL could inhibit osteoclast activation by cancer cells. In
this study, it was demonstrated that Cox-2 mRNA synthesis is
greatly reduced by 1mM ZOL treatment for 6h. This was
responsible for the decrease in Cox-2 protein level and the
consequent decrease in PGE2 secretion by MDA-MB-231 cells.
These decreases in Cox-2 expression and PGE2 secretion by ZOL
are independent of RhoA inactivation as they were not mimicked
by C3 exoenzyme and were not reversed by GGOH. Whereas Ras
was reported to be involved in Cox-2 expression in these cancer
cells (Gilhooly and Rose, 1999), Ras inhibition does not appear to
be involved in this Cox-2 inhibition by ZOL, as it occurs at low
concentrations that did not inhibit Ras activation. Although the
molecular mechanism of this inhibition was not yet elucidated, it is
suggested that it could contribute to the beneficial effect induced
by ZOL on the inhibition of metastatic breast-cancer-mediated
osteolysis. Interestingly, since ZOL, with its high affinity to hydroxy-
apatite, is concentrated on the bone surface, its effect could be
more important than that induced by other Cox-2 inhibitors,
which although reducing breast-cancer metastasis, have a reduced
affinity for bone in comparison to ZOL (Kundu and Fulton, 2002).
In summary, our results suggest that ZOL could be used not only
to treat cancer metastasis-induced osteolysis but also to prevent
metastasis. The growth inhibition of osteoclasts has been suggested
as the main mechanism of the inhibitory effect of ZOL on bone
metastases. In this study, a new concept was proposed by which, in
breast-cancer cells, ZOL inhibits the production of PGE2,
suggesting a decreased cooperation between osteoclasts and cancer
cells for inducing osteolysis. In addition, ZOL induces a potent
inhibition of both breast-cancer cell invasion and SDF-1-mediated
chemotactic effect. It may be useful to correlate these results with
clinical trials to test the efficacy of ZOL on the prevention of
metastases in patients with highly aggressive breast cancer. In
addition, as both Cox-2 and CXCR-4 inhibitions are RhoA-
independent, further investigations are required to determine
whether the invasion of cancer cells without RhoA activation could
be reduced by ZOL.
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